Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Shore

Showing results (411-420 of 422) with videos related to

Pageof 43
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 25, 2001
Infections with Ehrlichia chaffeensis and Ehrlichia ewingii in persons coinfected with human immunodeficiency virusC D Paddock, S M Folk, G M Shore, et al.
Nature Genetics|April 28, 2006
A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressivaEileen M Shore, Meiqi Xu, George J Feldman, et al.
Human Mutation|December 17, 2008
Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1Frederick S Kaplan, Meiqi Xu, Petra Seemann, et al.
Genetic Counseling (Geneva, Switzerland)|November 11, 2008
Response to "Mutations of the NOGGIN and of the activin A type I receptor genes in fibrodysplasia ossificans progressiva (FOP)" by Lucotte et alF S Kaplan, M Xu, G Feldman, et al.
Science (New York, N.Y.)|January 4, 2014
Pregnenolone can protect the brain from cannabis intoxicationMonique Vallée, Sergio Vitiello, Luigi Bellocchio, et al.
JBMR Plus|October 27, 2025
Medical guidelines for fibrodysplasia ossificans progressivaFrederick S Kaplan, Mona Al Mukaddam, Genevieve Baujat, et al.
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|June 4, 2011
A call for full public disclosure for donation after circulatory determination of death in childrenThomas A Nakagawa, Mark R Rigby, Susan Bratton, et al.
The Journal of Biological Chemistry|August 8, 2008
Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressivaToru Fukuda, Masakazu Kohda, Kazuhiro Kanomata, et al.
Frontiers in Endocrinology|December 3, 2021
Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz WorkshopRuben D de Ruiter, Bernard J Smilde, Gerard Pals, et al.
Nature Reviews. Endocrinology|July 1, 2018
Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus StatementGiovanna Mantovani, Murat Bastepe, David Monk, et al.
Pageof 43

Showing results (411-420 of 422) with videos related to

Sort By:
Pageof 43
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 25, 2001
Infections with Ehrlichia chaffeensis and Ehrlichia ewingii in persons coinfected with human immunodeficiency virusC D Paddock, S M Folk, G M Shore, et al.
Nature Genetics|April 28, 2006
A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressivaEileen M Shore, Meiqi Xu, George J Feldman, et al.
Human Mutation|December 17, 2008
Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1Frederick S Kaplan, Meiqi Xu, Petra Seemann, et al.
Genetic Counseling (Geneva, Switzerland)|November 11, 2008
Response to "Mutations of the NOGGIN and of the activin A type I receptor genes in fibrodysplasia ossificans progressiva (FOP)" by Lucotte et alF S Kaplan, M Xu, G Feldman, et al.
Science (New York, N.Y.)|January 4, 2014
Pregnenolone can protect the brain from cannabis intoxicationMonique Vallée, Sergio Vitiello, Luigi Bellocchio, et al.
JBMR Plus|October 27, 2025
Medical guidelines for fibrodysplasia ossificans progressivaFrederick S Kaplan, Mona Al Mukaddam, Genevieve Baujat, et al.
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|June 4, 2011
A call for full public disclosure for donation after circulatory determination of death in childrenThomas A Nakagawa, Mark R Rigby, Susan Bratton, et al.
The Journal of Biological Chemistry|August 8, 2008
Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressivaToru Fukuda, Masakazu Kohda, Kazuhiro Kanomata, et al.
Frontiers in Endocrinology|December 3, 2021
Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz WorkshopRuben D de Ruiter, Bernard J Smilde, Gerard Pals, et al.
Nature Reviews. Endocrinology|July 1, 2018
Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus StatementGiovanna Mantovani, Murat Bastepe, David Monk, et al.
Pageof 43